Have a feature idea you'd love to see implemented?
Let us know!
ALLK Allakos Inc
Price (delayed)
$1.25
Market cap
$111.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
$121.15M
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab
Highlights
Allakos's debt has decreased by 8% YoY and by 2.2% from the previous quarter
ALLK's EPS has dropped by 53% year-on-year but it is up by 4.5% since the previous quarter
The net income has contracted by 36% YoY but it has grown by 3.9% from the previous quarter
The equity has dropped by 67% year-on-year and by 19% since the previous quarter
The company's quick ratio has shrunk by 62% YoY and by 12% QoQ
Key stats
What are the main financial stats of ALLK
Market
Valuations
Earnings
Shares outstanding
88.85M
Market cap
$111.06M
Enterprise value
$121.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$214.93M
EBITDA
-$207.68M
Free cash flow
-$103.33M
Per share
Balance sheet
Liquidity
EPS
-$2.35
Free cash flow per share
-$1.17
Book value per share
$0.95
Revenue per share
$0
TBVPS
$1.77
Total assets
$156.46M
Total liabilities
$72.46M
Debt
$36.58M
Equity
$84M
Working capital
$92.05M
Debt to equity
0.44
Current ratio
3.57
Quick ratio
3.43
Net debt/EBITDA
-0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-95.7%
Return on equity
-142.6%
Return on invested capital
-127.6%
Return on capital employed
-178.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLK stock price
How has the Allakos stock price performed over time
Intraday
2.46%
1 week
19.05%
1 month
91.37%
1 year
-31.69%
YTD
-54.21%
QTD
91.37%
Financial performance
How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$214.9M
Net income
-$206M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 36% YoY but it has grown by 3.9% from the previous quarter
The operating income has contracted by 34% YoY but it has grown by 4.1% from the previous quarter
Growth
What is Allakos's growth rate over time
Valuation
What is Allakos stock price valuation
P/E
N/A
P/B
1.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS has dropped by 53% year-on-year but it is up by 4.5% since the previous quarter
ALLK's price to book (P/B) is 71% less than its 5-year quarterly average of 4.5 but 17% more than its last 4 quarters average of 1.1
The equity has dropped by 67% year-on-year and by 19% since the previous quarter
Efficiency
How efficient is Allakos business performance
ALLK's return on equity has dropped by 180% year-on-year and by 25% since the previous quarter
The return on assets has dropped by 133% year-on-year and by 14% since the previous quarter
The ROIC has plunged by 116% YoY and by 15% from the previous quarter
Dividends
What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLK.
Financial health
How did Allakos financials performed over time
Allakos's total assets is 116% more than its total liabilities
The current ratio has shrunk by 65% YoY and by 13% QoQ
The company's quick ratio has shrunk by 62% YoY and by 12% QoQ
Allakos's debt is 56% less than its equity
ALLK's debt to equity has soared by 175% YoY and by 22% from the previous quarter
The equity has dropped by 67% year-on-year and by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.